Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silo Pharma filings document a Nasdaq-listed Nevada operating company with common stock registered under symbol SILO and a developmental-stage biopharmaceutical business. Its registration statements and offering-related disclosures address registered securities, capital structure, smaller reporting company status, and securities transactions associated with a company developing CNS, psychiatric and chronic-pain therapeutic programs.
Recent 8-K and proxy filings record material agreements, equity issuances, shareholder voting matters, board and compensation-plan actions, and governance changes. Disclosures also cover asset purchases for QwikAgents and cryptocurrency-related software, formation of a cryptocurrency advisory board, registered and private securities transactions, and the amendment of the company’s 2020 omnibus equity incentive plan.
Silo Pharma (SILO) reported results from its October 24, 2025 annual meeting. Shareholders approved giving the Board discretionary authority to effect a reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-20, without reducing the authorized shares, which may be effected at any time before October 24, 2026.
Shareholders also approved an amendment to the 2020 Omnibus Equity Incentive Plan to increase the stock reserve to 1,400,000 shares from 470,000. All four directors—Eric Weisblum, Wayne Linsley, Kevin Muñoz and Jeff Pavell—were re-elected, and Salberg & Company, P.A. was ratified as independent auditor for fiscal 2025. An adjournment proposal was approved as well. A quorum of 5,142,415 shares was represented in person or by proxy.
SILO issuer Silo Pharma, Inc. has a Schedule 13G filed by SEG Opportunity Fund, LLC reporting beneficial ownership of 952,381 shares of common stock, representing 7.1% of the class based on 13,318,273 shares outstanding after a Registered Direct Offering closed October 1, 2025. The filing shows shared voting and shared dispositive power over those shares and no sole voting or dispositive power.
The filer certifies the shares were not acquired to change or influence control of the issuer. The filing is dated 10/03/2025 and lists SEG Opportunity Fund as a New York LLC with its address in Roslyn, NY. This is a passive ownership disclosure under Schedule 13G.
Silo Pharma, Inc. entered into a securities purchase agreement with institutional investors to raise approximately $2.5 million in gross proceeds. The company sold 2,857,143 shares of common stock at $0.875 per share under its effective shelf registration statement.
For each share purchased, investors received an unregistered warrant to buy one additional share of common stock at an exercise price of $0.75 per share. These warrants are exercisable immediately and expire five years after a registration statement covering the warrant shares becomes effective.
Silo engaged H.C. Wainwright & Co. as exclusive placement agent, agreeing to pay cash fees totaling 8.5% of gross proceeds and to issue placement agent warrants for up to 214,285 shares at an exercise price of $1.0938 per share. The company plans to use net proceeds for working capital and general corporate purposes and agreed to short-term restrictions on issuing additional equity and a one-year prohibition on variable rate transactions.
Silo Pharma, Inc. (SILO) published a prospectus supplement describing a securities offering intended to raise net proceeds of approximately $2.15 million after placement agent fees and estimated expenses. The supplement identifies an offering price and placement agent fees that produce gross proceeds shown as $2,312,500.12 before expenses and net proceeds of about $2.15 million to be used for general corporate and working capital purposes. The document lists 2,857,143 shares in connection with Unregistered Warrants and total potential dilution from numerous outstanding options and warrants, including large tranches exercisable at prices ranging from $0.60 to $6.25 per share and specific counts such as 4,773,340 shares issuable upon exercise of May 2025 Warrants at $0.60 and 2,857,143 shares issuable upon exercise of Unregistered Warrants at $0.75. The filing emphasizes high risks, including need for additional financing, no history of profitable operations, regulatory and controlled-substance risks for psilocybin-based candidates, potential dilution, and Nasdaq listing risk.
Silo Pharma, Inc. presents a definitive proxy statement covering board composition, governance matters and executive compensation. The board is nominating four directors including Eric Weisblum (Chairman, CEO, President) and three director nominees: Wayne Linsley, Dr. Kevin Muñoz and Dr. Jeff Pavell. The proxy describes voting standards for director elections and shareholder approvals tied to majority or plurality votes as applicable.
Key compensation disclosures show Daniel Ryweck's employment agreement calling for a $60,000 annual base salary and eligibility for an annual discretionary bonus up to $60,000. The filing reports company contributions to executives' 401(k) plans and payment of health insurance premiums. The proxy discloses equity plan details: an Amended and Restated 2020 Omnibus Equity Incentive Plan expanded to 470,000 shares and current reserved instruments including 8,295,072 shares for warrants and 467,850 shares for options/RSUs. The statement also includes a shareholder-authorized reverse stock split framework to be fixed within an approved ratio by the board.
Silo Pharma, Inc. (SILO) preliminary proxy extracts show the company is soliciting shareholder votes on director nominations, auditor ratification, compensation practices and a potential reverse stock split. The board nominees include Eric Weisblum (Chairman, CEO, President), Wayne D. Linsley, Dr. Kevin Muñoz and Dr. Jeff Pavell. The filing discloses executive pay mechanics: Eric Weisblum is the PEO, Daniel (Dan) Ryweck is CFO with a written employment agreement establishing a $60,000 base salary and eligibility for an annual discretionary bonus up to $60,000. The Amended and Restated 2020 Omnibus Equity Incentive Plan was adopted, increased to 470,000 shares and includes clawback language. The proxy notes existing reserved shares for warrants, options and RSUs and describes a board-authorized reverse stock split to be set within a shareholder-approved range.
Silo Pharma, Inc. (SILO) reported consolidated interim results showing a net loss of $2,235,730 for the six months ended June 30, 2025, compared with a $1,733,446 loss in the same period of 2024, reflecting larger operating losses. Research and development and professional fees were significant components of operating expenses, with R&D of $1,311,209 and professional fees of $573,416 for the six months in 2025. Net cash used in operating activities reflected the loss offset by non-cash items (amortization $5,565, stock-based compensation $17,445, net realized gain $3,911) and working capital changes.
The company reported net cash provided by investing activities of $1,259,483 (principally proceeds from sale of short-term investments) and net cash provided by financing activities of $2,093,958 (including $1,593,897 from sale of common stock/pre-funded warrants and $500,061 from exercises), producing a net increase in cash of $427,873 for the period.
Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company advancing therapies for PTSD, fibromyalgia, Alzheimer’s and multiple sclerosis. The company reported cash and cash equivalents of $4.33 million and short-term investments of $1.93 million, giving total assets of $6.65 million and working capital of $5.32 million. Management states available cash and liquid investments are sufficient to meet obligations for at least twelve months.
Operating results show a six-month net loss of $2.24 million versus $1.73 million a year earlier, driven by higher research and development expense of $1.31 million (six months) and total operating expenses of $2.38 million. License fee revenue remains nominal ($36,051 six months) with one licensee accounting for 100% of that revenue. Financing activity increased shares outstanding from 4.48 million to 8.65 million and generated net proceeds of $1.59 million from a May 2025 offering. Outstanding warrants totaled 8,295,072, and intangible assets include a Columbia license revised to $235,000.
This Schedule 13G/A reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively may beneficially own 838,081 shares of Silo Pharma common stock, representing approximately 9.99% of the outstanding common shares. That reported stake primarily reflects 833,334 shares issuable upon exercise of one warrant and 4,747 shares issuable upon exercise of a second warrant.
The filing shows the Reporting Persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over the 838,081 shares. Several additional warrants are subject to blocker provisions that prevent exercise to the extent that conversion would push ownership above certain thresholds; excluding those blocked amounts, the Reporting Persons could be deemed to beneficially own 2,392,524 shares. The filing includes a certification that the securities are not held to change or influence control of the issuer.
Silo Pharma (SILO) filed an 8-K to disclose a strategic shift toward digital assets. On 4 Aug 2025 the Board formed a Cryptocurrency Advisory Board of up to three members to guide a newly adopted cryptocurrency treasury strategy. The Board simultaneously appointed Corwin Yu as the first advisor and executed an agreement granting him 45,000 stock options at an exercise price of $0.7757. The options vest in 12 equal monthly tranches under the Amended & Restated 2020 Omnibus Equity Incentive Plan. A press release announcing the initiative was issued on 5 Aug 2025 and filed as Exhibit 99.1.
No financial results, guidance, or capital-raising transactions were reported. The filing is limited to governance changes and does not alter prior disclosures.